11th Annual:
Reporting on the Latest Advancements and Data in IO
Immuno-Oncology 360° offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting IO to fight a wider range of cancers.
IO360° Delivers 3 Key Benefits
1. Access to KOLs and stakeholders in the science and business communities, reporting on cutting-edge research and trends shaping IO technology, investment, and innovation
2. Presentations featuring 100+ talks on the latest innovative research delivered by international leaders from academia, investors, and industry representatives
3. 10+ hours of networking and business development opportunities to connect with 550+ attendees who specialize in cancer immunotherapy
2025 Key Topics
Biomarkers/Assay Development
Business and Investing Aspects
Discovery/Preclinical
Autoimmune Disease & IO
ADCs & IO
IO Combinations
Translational Science
Imaging Advancements
Cell Therapy
Clinical Operations
Clinical Developments
Neoadjuvant/Adjuvant Therapy
New Tech in Transformational Biology
And More
Translational Science & Clinical Development Trailblazers
.jpeg)
Dr Georg Schett
FAU Erlangen-Nürnberg
.jpeg)
Dr Jonathan Rosenberg
MSKCC
.jpeg)
Dr Alexander Eggermont
Princess Máxima Center for Pediatric Oncology
.jpg)
Dr Charles Drake
J&J Innovative Medicine
.jpeg)
Dr Delfi Krishna
Immatics Biotechnologies
.jpeg)
Dr Olivier Rixe
Daiichi Sankyo
.jpeg)
Dr Gregory Sawyer
Moffitt Cancer Center
.jpg)
Dr Naiyer Rizvi
Synthekine
.jpeg)
Dr Rosanna Ricafort
BMS
Transformational Biology Experts
.jpg)
Dr William Hawkins
MUSC Hollings Cancer Center
.jpg)
Dr Dushen Chetty
Novartis
Dr Raluca Verona
AbbVie
.jpg)
Dr Kazusa Ishii
NCI
Innovators in IO Biotech
Dr Priti Hegde
Kite Pharma
Dr Theresa LaValle
Coheres Biosciences
Dr Roy Baynes
Eikon Therapeutics
.jpg)
Dr Rachel Humphrey
Normunity
Investment and Business Development
.jpg)
Dr Andrew Baum
Pfizer
.jpg)
Rajiv Kaul
Fidelity Investments
.jpg)
Rakhshita Dhar
Leaps by Bayer
.jpg)
Dr Emmett Schmidt
Merck
Kallie Dirks
Morgan Stanley
Clinical Operations Leadership
.jpg)
Andy Lee
Merck
.jpg)
Sarah White
Bringham and Women’s Hospital
.jpg)
Marta Arias-Salgado
Merck
Dr Michael Ku
Pfizer
.jpg)
Luisa Freitas Dos Santos
GSK
Networking and Business Opportunities
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk
Scheduled Networking:
IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
• Early evening organized historical walks of downtown Brooklyn
2025 Event Features
.png)
.png)
.png)
Who Attends
.png)
Companies Attending:
• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• BMS
• Boehringer Ingelheim
• City of Hope
• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center
• Merck
• Moderna
• Morgan Stanley
• Mount Sinai
• MPM BioImpact
• NCI
• Novartis
• OrbiMed
• RA Capital
• Regeneron
• Stanford University
• Stifel
• Takeda
• And More!
"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics
Dr Kristen Hege Looks Back at Lessons Learned from a Career in CAR-T Therapy
Taking Lessons from the Last Decade of IO to Develop the Next Wave of Therapeutics
Dr Roy Baynes on Strategy Development for Keytruda
2025 Sponsors
